19
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Preventive treatment of intrauterine device-induced menstrual blood loss with tranexamic acid in Chinese women

, , , , &
Pages 1126-1129 | Received 27 Apr 2007, Published online: 03 Aug 2009
 

Abstract

Objectives. To investigate whether tranexamic acid (Transamin®) therapy reduces the amount of menstrual blood loss (MBL) and occurrence of menorrhagia after intrauterine device (IUD) insertion. Methods. Some 175 Chinese women attending for IUD insertion were equally assigned into 2 Transamin® groups (1,000 and 500 mg, twice daily) and a placebo group. Their MBL was recorded with a pictorial chart in 3 subsequent menstrual cycles after insertion, while the MBL of 64 patients, collecting used sanitary towels, was also measured by an alkaline hematin method. Results. A significant decline in post-insertion MBL and occurrence of menorrhagia was found in the 2 Transamin® groups compared with the placebo group (p<0.05), whereas the difference in the results from the pictorial chart score was not statistically significant between the 1 g group and placebo group. Conclusion. Transamin® treatment with a generally recommended dosage can effectively reduce the amount of IUD-induced MBL and prevent menorrhagia in Chinese women. A lower dosage than recommended (50% of recommended dosage) may have a similar preventive effect.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.